Trial Profile

Phase 2 Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enobosarm (Primary)
Indications Urinary-Stress-Incontinence
Focus Therapeutic Use
Sponsors GTx

Most Recent Events

12 Sep 2023 Status changed from discontinued to withdrawn prior to enrolment due to lack of efficacy .
27 Sep 2018 Status changed from recruiting to discontinued due to lack of efficacy
11 Jun 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com